Aurin Tricarboxylic Acid Inhibits Platelet Adhesion to Collagen by Binding to the 509-695 Disulphide Loop of von Willebrand Factor and Competing with Glycoprotein Ib

J P Girma; E Fressinaud; O Christophe; C Rouault; B Obert; Y Takahashi; D Meyer

doi:10.1055/s-0038-1646348

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1992; 68(06): 707-713
DOI: 10.1055/s-0038-1646348

Original Article

Schattauer GmbH Stuttgart

Aurin Tricarboxylic Acid Inhibits Platelet Adhesion to Collagen by Binding to the 509-695 Disulphide Loop of von Willebrand Factor and Competing with Glycoprotein Ib

Authors

J P Girma

¹Inserm U.143, Hôpital de Bicêtre, Paris, France
E Fressinaud

²Centre Départemental de Transfusion, Angers, France
O Christophe

¹Inserm U.143, Hôpital de Bicêtre, Paris, France
C Rouault

¹Inserm U.143, Hôpital de Bicêtre, Paris, France
B Obert

¹Inserm U.143, Hôpital de Bicêtre, Paris, France
Y Takahashi

³Department of Pediatrics, Nara Medical College, Nara, Japan
D Meyer

¹Inserm U.143, Hôpital de Bicêtre, Paris, France

Abstract

PDF Download

Summary

Aurin tricarboxylic acid (ATA) is known to inhibit ristocetin-induced platelet agglutination but not arachidonic acid-, epinephrine- or ADP-induced aggregation. Its capacity to abolish human von Willebrand factor (vWF)-platelet interactions was further investigated by measurement of platelet adhesion to collagen, platelet agglutination tests and binding studies. In flowing blood using parallel-plate perfusion chambers and human collagen, ATA inhibited platelet adhesion to completion in a dose-dependent manner only at the highest shear rate tested (2,600 s^–1). It was without effect at 100 and 650 s^–1. ATA completely abolished vWF-dependent platelet agglutination induced by ristocetin, botrocetin and asialo-vWF, respectively. ¹²⁵I-vWF binding to ristocetin- and botrocetin-treated platelets, to heparin and to sulfatides as well as ¹²⁵I-botrocetin binding to vWF was competitively inhibited by ATA. By contrast, binding of ¹²⁵I-vWF to collagen was not affected. To further localize the domain of vWF interacting with ATA, experiments of inhibition of binding of selected ¹²⁵I-monoclonal antibodies (MoAbs) to immobilized vWF by ATA were performed. Our data led to the conclusion that: 1) the interaction of ATA with vWF involves sequences of the A1 disulphide loop of vWF (residues 509–695) and close epitopes which interact with GPIb and 2) the inhibition of platelet adhesion by ATA occurs only at a high shear rate where vWF is known to play a key role. Thus ATA, which blocks the vWF/GPIb pathway by interfering with vWF and not with platelets, is a potential tool in preventing the early stages of thrombosis.

PDF (848 kb)

References

REFERENCES
1 Baruch D, Bahnak B, Girma JP, Meyer D. von Willebrand Factor and platelet function. In: Platelet Disorders. Caen J. (ed) Bailliere’s Clin Haematol: 1989. pp 627-672
2 Kalafatis M, Takahashi Y, Girma JP, Meyer D. Localization of a collagen-interactive domain of human von Willebrand Factor between amino acid residues Gly 911 and Glu 1,365. Blood 1987; 70: 1577-1583
3 Pareti FI, Fujimura Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM. Isolation and characterization of a collagen binding domain in human von Willebrand Factor. J Biol Chem 1986; 261: 15310-15315
4 Pareti FJ, Niiya K, McPherson JM, Ruggeri ZM. Isolation and characterization of two domains of human von Willebrand Factor that interact with fibrillar collagen types I and III. J Biol Chem 1987; 262: 13835-13841
5 Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of von Willebrand Factor domain interacting with glycoprotein lb, heparin and collagen and characterization of its three distinct functional sites. J Biol Chem 1989; 264: 17361-17367
6 De Groot PG, Ottentof-Rovers M, van Mourik JA, Sixma JJ. Evidence that the primary binding site of von Willebrand Factor that mediates platelet adhesion on subendothelium is not collagen. J Clin Invest 1988; 82: 65-73
7 Christophe O, Obert B, Meyer D, Girma JP. The binding of von Willebrand Factor to sulfatides is distinct from those interacting with glycoprotein lb, heparin, and collagen and resides between amino acid residues Leu 512 and Lys 673. Blood 1991; 78: 2310-2317
8 Berndt MC, Booth WJ, Andrews RK, Castaldi PA. Definition of von Willebrand Factor (vWF)-GPIb-IX complex interaction using vWF peptides. Thromb Haemostas 1991; 65: 748 (Abstract)
9 Fretto LJ, Fowler WE, McCaslin DR, Erickson HP, McKee PA. Substructure of human von Willebrand Factor: proteolysis by V8 and characterization of two functional domains. J Biol Chem 1986; 261: 15679-15689
10 Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a heparin binding domain peptide of human von Willebrand Factor. J Biol Chem 1992; 267: 8857-8862
11 Mohri H, Fujimura Y, Shima M, Yosohioka A, Houghten RA, Ruggeri ZM, Zimmermann TS. Structure of von Willebrand Factor domain interacting with glycoprotein lb. J Biol Chem 1988; 263: 17901-17904
12 Girma JP, Kalafatis M, Pietu G, Lavergne JM, Chopek MW, Edgington TS, Meyer D. Mapping of distinct von Willebrand Factor domains interacting with platelet GPIb and GPIIb/IIIa and with collagen using monoclonal antibodies. Blood 1986; 67: 1356-1366
13 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand’s disease and the Bernard-Soulier syndrome. J Lab Clin Med 1978; 92: 750-764
14 Baumgartner HR, Tschopp TB, Meyer D. Shear rate-dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human Factor VIII/von Willebrand Factor. Br J Haematol 1980; 44: 127-139
15 Bolhuis PA, Sakariassen KS, Sander HJ, Bouma BN, Sixma JJ. Binding of Factor VIII/von Willebrand Factor to subendothelium precedes platelet adhesion and enhances platelet spreading. J Lab Clin Med 1981; 97: 568-576
16 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand Factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand Factor. Blood 1983; 61: 099-111
17 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Heliums JD. Involvement of large plasma von Willebrand Factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-1461
18 Howard MA, Perkin J, Salem HH, Firkin BG. The agglutination of human platelets by botrocetin: evidence that botrocetin and ristocetin act at different sites on the factor VIII molecule and platelet membrane. Br J Haematol 1984; 57: 25-35
19 Sugimoto M, Mohri H, McClintock RA, Ruggeri ZM. Identification of discontinuous von Willebrand Factor sequences involved in complex formation with botrocetin. J Biol Chem 1991; 266: 18172-18178
20 De Marco L, Girolami A, Russel S, Ruggeri ZM. Interaction of asialo von Willebrand Factor with glycoprotein lb induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest 1985; 75: 1198-1203
21 Phillips MD, Moake JL, Nolasco L, Turner N. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand Factor and platelets. Blood 1988; 72: 1898-1903
22 Strony J, Phillips M, Brands D, Moake J, Adelman B. Aurintricar-boxylic acid in a canine model of coronary artery thrombosis. Circulation 1990; 81: 1106-1114
23 Weinstein M, Vosburg E, Phillips M, Turner N, Chute-Rose L, Moake J. Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand Factor interaction with platelet glycoprotein lb. Comparison with other polyanionic and polyaromatic polymers. Blood 1991; 78: 2291-2298
24 Sakariassen KS, Aarts PAM, de Groot PhG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 1983; 102: 522-535
25 Sakariassen KS, Joss R, Muggli R, Kuhn H, Tschopp TB, Sage H, Baumgartner HR. Collagen type III induced ex vivo thrombogenesis in humans: Role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 1990; 10: 276-284
26 Miller EF, Rhodes RK. Preparation and characterization of the different types of collagen. Methods Enzymol 1982; 82: 32-41
27 Bruns RR, Gross J. High resolution analysis of the quarter stagger model of the collagen fibril. Biopolymers 1977; 13: 931-941
28 Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 1961; 93: 440-447
29 Muggli R, Baumgartner HR, Tschopp TB, Keller H. Automated microdensitometry and, protein assays as a measure for platelet adhesion and aggregation on collagen-coated slides under controlled flow conditions. J Lab Clin Med 1980; 95: 195-207
30 Sakariassen KS, Kuhn H, Muggli R, Baumgartner HR. Growth and stability of thrombi in flowing blood: assessment of platelet-surface interactions with computer-assisted morphometry. Thromb Haemostas 1988; 60: 392-398
31 Baumgartner HR, Muggli R. Adhesion and aggregation: morphological demonstration and quantitation in vivo and in vitro. In: Platelets in Biology and Pathology. Gordon JL. (ed) Elsevier/North Holland Biomedical, Amsterdam: 1976. pp 23-60
32 Thorell L, Blombäck B. Purification of the factor VIII complex. Thromb Res 1984; 35: 431-450
33 Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand Factor for binding to platelet membrane glycoprotein lb. Thromb Haemostas 1990; 64: 326-332
34 Takahashi Y, Kalafatis M, Girma JP, Sewerin K, Andersson LO, Meyer D. Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand Factor. Blood 1987; 70: 1679-1682
35 Layet S, Girma JP, Obert B, Peynaud-Debayle E, Bihoreau N, Meyer D. Evidence that a secondary binding and protecting site for Factor VIII on von Willebrand Factor is highly unlikely. Biochem J 1992; 282: 129-137
36 Fine JM, Steinbuch M. A simple technique for the isolation of monoclonal IgG and IgA. Rev Eur Et Clin Biol 1970; 15: 1115-1121
37 Fujimura Y, Titani K, Usami Y, Suzuki M, Oyama R, Matsui T, Fukui H, Sugimoto M, Ruggeri ZM. Isolation and chemical characterization of two structurally and functionally distinct forms of botrocetin, the platelet coagglutinin isolated from the venom of Bothrops Jararaca. Biochemistry 1991; 30: 1937-1964
38 Pietu G, Fressinaud E, Girma JP, Nieuwenhuis HK, Rothschild C, Meyer D. Binding of von Willebrand factor to collagen and to collagen-stimulated platelets. J Lab Clin Med 1987; 109: 637-646
39 Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand Factor and platelet aggregating factor. J Lab Clin Med 1975; 85: 318-328
40 Fraker PJ, Speck JC. Proteins and cell membrane iodinations with a sparingly soluble chloroamide, 1, 3, 4, 6-tetrachloro-3a, 6a diphenyl-glycoluril. Biochem Biophys Res Commun 1978; 80: 849-857
41 Fujimura Y, Titani K, Holland LZ, Roberts JR, Kostel P, Ruggeri ZM, Zimmermann TS. A heparin-binding domain of human von Willebrand Factor. Characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. J Biol Chem 1987; 262: 1734-1739
42 Sakariassen KS, Nievelstein PFEM, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins IIb and IIb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986; 63: 681-691
43 Fressinaud E, Baruch D, Girma JP, Sakariassen KS, Baumgartner HR, Meyer D. von Willebrand Factor-mediated adhesion to collagen involves platelet membrane glycoprotein IIb-IIIa as well as glycoprotein Ib. J Lab Clin Med 1988; 112: 58-67
44 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM. The role of von Willebrand Factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-1240
45 Bisson C, Ceriani R, Bader R, Cremonesi P, Mannucci PM, Paggella PG, Pareti PI. Binding of certain dyes to vWF through different sites. Thromb Res 1991; suppl XIII 13 (Abstract)
46 Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand Factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-1793